Description
PrymaLab · Research use only
Livagen 20mg Nasal Spray
Livagen tetrapeptide (Lys-Glu-Asp-Ala), 20 mg in sterile solution in a spray bottle
Livagen nasal spray contains Lys-Glu-Asp-Ala, the four-residue peptide listed as KEDA in the Khavinson bioregulator series. The bottle holds 20 mg of Livagen in sterile bacteriostatic water, at no more than 0.2% w/v according to the safety data sheet, supplied already in solution. Livagen research consists of a short list of chromatin and cytogenetic studies in cultured human cells, and nasal drug delivery is a separate field that has not examined this peptide.
Specifications
| Property | Value |
|---|---|
| Compound | Livagen (Lys-Glu-Asp-Ala (KEDA)) |
| CAS number | Not assigned |
| Molecular formula | C18H31N5O9 |
| Contents | Livagen: 20 mg per bottle (≤ 0.2% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Safety data sheet | PL-SDS-104 |
What is in the bottle
The solution holds 20 mg of the KEDA tetrapeptide, the same compound sold dry in the Livagen 20 mg vial, at or below 0.2% w/v in bacteriostatic water with 0.9% benzyl alcohol as preservative. The peptide itself is unclassified on the safety data sheet. Benzyl alcohol is the hazardous component: harmful if swallowed or inhaled, irritating to the eyes and able to cause allergic skin reactions.
Keep the bottle capped and upright at 2 to 8 °C, out of light, and do not freeze it. More on keeping peptide solutions is in peptide storage and stability.
What the research covers
Interest in the nose as a route for peptides comes from pharmaceutical research in general. Illum’s 2002 review covered nasal delivery systems being developed for conventional drugs and peptides and discussed evidence that some drugs pass directly from the nose to the brain along the olfactory pathway1. It names no Khavinson peptide, and none of the Livagen studies in these references used the nasal route.
What Livagen has been tested for is chromatin structure. In leukocytes from donors aged 75 to 88 it was one of five peptides that activated ribosomal genes and opened up condensed chromatin2. In a separate series of lymphocyte cultures from people over 80, Lezhava and Jokhadze found it reactivated heterochromatin and reduced chromosomal aberrations induced by cobalt chloride3. These are culture results with cells from donors. They say nothing about absorption through a mucous membrane or about the peptide’s stability in a spray solution.
There are no animal or human studies of Livagen among these references, and the work comes from Khavinson’s institute and its collaborators. The Livagen guide sets out the full list of studies and the limits of each.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the bottle, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Is the spray the same Livagen as the vial and pen?
Yes, the same Lys-Glu-Asp-Ala tetrapeptide in each. The vial is dry powder kept frozen, while the spray and pen are sterile solutions in bacteriostatic water kept at 2 to 8 °C. Each of the three listings contains 20 mg of Livagen.
How much peptide does the bottle contain?
Twenty milligrams, dissolved at no more than 0.2% w/v according to the safety data sheet; the label on the bottle gives the amount. If a study calls for a concentration chosen in the lab, the freeze-dried vial supplies a known mass instead.
Has Livagen been studied as a nasal spray?
Not in any paper cited here. The Livagen studies are culture experiments on donated human cells, and the nasal delivery review on this page discusses drugs and peptides generally without mentioning Livagen.
Is Livagen nasal spray for human use?
No. It is sold for laboratory research only and has no approval for human or veterinary use from the FDA or any other body. It must not be used in people or animals.
References
- Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184-9. DOI · PubMed
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. DOI · PubMed
- Lezhava T, Jokhadze T. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Ann N Y Acad Sci. 2007;1100:387-99. DOI · PubMed
Research use only
For laboratory research use only. Livagen 20mg Nasal Spray is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of Livagen
Livagen is also stocked as Livagen 20mg preloaded 3ml pen. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.